34,017 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by Qsemble Capital Management LP

Qsemble Capital Management LP bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 34,017 shares of the company’s stock, valued at approximately $224,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $5,769,000. Pier 88 Investment Partners LLC raised its holdings in shares of Recursion Pharmaceuticals by 442.1% during the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after acquiring an additional 109,210 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Recursion Pharmaceuticals by 6,439.6% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after acquiring an additional 167,302 shares during the period. Scientech Research LLC acquired a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $1,052,000. Finally, Ghisallo Capital Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $8,250,000. 89.06% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. This represents a 1.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,682 shares of company stock worth $1,088,111. 15.75% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RXRX. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $6.38 on Thursday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $6.59 and a 200 day simple moving average of $7.45. The company has a market cap of $1.83 billion, a P/E ratio of -3.85 and a beta of 0.81. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.43) earnings per share. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.